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Abstract 
 
Introduction: Subclinical rejection (SCAR) of renal 
allografts refers to graft lymphocytic infiltration 
taking acute rejection histologic pattern despite 
stable renal function. There are no data to suggest 
that subclinical tubulointerstitial inflammation is 
regulatory or in any way beneficial to the graft. We 
have investigated whether C57BL/6 CD8 T cells 
home to long term engrafted (LTE) DBA/2 skin 
allografts and if it is protecting or rejecting. 
Methods and results: We transplanted two groups 
of B6 CD4 KO mice, 6 mice each, with MHC 
mismatched DBA/2 skin. Only the 1st group was 
treated with Rapamycin (RPM) as reported. After 
100 days of LTE, we challenged RPM treated hosts 
with a 2nd DBA/2 skin graft. The 2
nd
 but not the 1
st
 
graft was rejected. Then we investigated the 
functional effects of graft inflitrating CD8 T cells. 
DBA/2 skin grafts were harvested 100 days 
posttransplantation from (i) RPM treated B6 CD4 
ko mice (N=5) and (ii) skin autografts (N=5) in 
DBA/2 recipients. LTE DBA/2 allografts or control 
DBA/2 autografts were then transplanted onto 
C57BL/6-Rag KO hosts, and peripheral blood 
lymphocytes (PBL) samples were collected 30 days 
post skin transplantation. CD8T cells can not be 
detected in PBL of naïve RAG-/- mice. 4.6 % CD8 
T cells are detected in PBL of RAG-/- recipients of 
LTE allografts, but not in recipients of syngeneic 
grafts. To test the protective function of the graft 
homing CD8 T cells (from LTE RPM mice) that 
expanded by homeostatic proliferation and are           
------------------                                                      
Correspondence and offprint requests to: Dr. Basset El Essawy, Head of 
Nephrology Unit - Internal medicine department; New Damietta Al Azhar 
Faculty of medicine, Egypt. Email: belessawy@gmail.com         
 
present in PBL of the RAG-/-, 0.2 x 10
6
 CD8 T 
cells from naive CD4KO mice were adoptively 
transferred into the RAG-/- hosts bearing the LTE 
DBA/2 allografts or DBA/2 autografts 30 days 
following skin transplantation. Survival of LTE 
DBA/2 skin allografts transplanted onto RAG-/- 
mice were significantly prolonged.  
Conclusion: Graft infiltrating CD8 T cells are 
regulatory and functionally active to protect 
allograft from rejection. 
 
Introduction 
 
The presence of lymphocytic infiltration in solid 
organ transplantation has been defined as acute 
cellular rejection when it is associated with graft 
dysfunction [1] and subclinical rejection (SCAR) 
when the graft function is quescient [1]. The 
assessment of allograft histology through 
prospective protocol biopsies was originally carried 
out for monitoring the advent of histopathologic 
lesions in clinically stable allografts [2]. The 
presence of asymptomatic tubulointerstitial cellular 
infiltrates has been defined as subclinical rejection 
[1]. The incidence of SCAR varies between 5% and 
15% with current maintenance immunosuppressive 
drug regimens [3]. 
The only pervious single randomized clinical trial 
of biopsy and corticosteroid therapy demonstrated 
significantly improved early structural and 
functional outcomes, and a (nonsignificant) 17% 
risk reduction in 4-year graft survival [4]. Same 
authors, almost a decade later have reported that 
early protocol biopsies and corticosteroid treatment 
of subclinical rejection seem to have no benefit on 
short-term outcomes in renal transplant recipients 
 being treated with tacrolimus, mycophenolate and 
prednisone [5]. 
In kidney transplant situations and despite many 
similarities between SCAR and clinical acute 
rejection exist, the inflammatory activated cell 
infiltrates are not completely identical while graft 
cytokine profiles and counteractive immune 
responses are characterized by subtle differences 
that could explain why SCAR is not accompanied 
by immediate graft dysfunction. Evidence that 
SCAR contributes to chronic allograft damage 
(interstitial fibrosis and tubular atrophy) and 
negatively affects graft outcome is counterbalanced 
by the scarcity of controlled data proving the 
beneficial effect of SCAR treatment [6-8]. 
To address this issue we used a skin transplant 
model in a CD4 KO mice (to study it in a single cell 
level) using a RPM treatment as it was reported to 
have a profound effect on CD8 T cells [9]. We 
investigated whether CD8 T cells home to LTE 
DBA/2 skin allografts and if these infiltrating 
lymphocytes have a functional effect (i.e. rejecting 
or protecting) in the skin allografts.  
 
Material and methods 
 
Animals: Male B6.CD4 knockout (KO; H-2
b
), 
DBA/2 (H-2
d
) mice, C3H/He (H-2
k
) and C57BL/6J-
Rag knockout (KO) mice 8–10 wk old, were 
purchased from Jackson Laboratory (Bar Harbor, 
ME). Animal use and care conformed to the 
guidelines established by the animal care committee 
at Beth Israel Deaconess Medical Center (Boston, 
MA). 
Reagents: All Abs used for cell surface staining 
were purchased from BD Pharmingen (San Diego, 
CA) unless indicated otherwise: FITC anti-mouse 
CD4 (clone RM4-5), CyChrome anti-mouse CD8 
(clone 53-6.7), FITC anti-mouse CD8 and FITC-
isotype control Abs. PE anti-CD3, PE anti-TCR. 
Rapamycin (RPM) (obtained from Wyeth-Ayerst) 
(Princeton, NJ) was prepared in carboxymethyl 
cellulose for i.p. injections. 
Skin transplantation and immunosuppression 
protocol: Full-thickness tail skin grafts (1 cm
2
) from 
donor mice were transplanted onto the thoracic wall 
of recipient mice. The skin grafts were secured with 
an adhesive bandage for the initial 7 days. One 
group of recipient mice was treated with RPM 
consisted of 3 mg/kg/day i.p. on days 0,1, and 2, 
followed by treatment every other day for 2 weeks 
as previously reported [9], while the second group 
was not treated. Graft survival was assessed by 
daily visual inspection. Rejection was defined as the 
complete necrosis and loss of viable skin tissue. 
Skin allografts from long term engrafted (LTE) 
(>100 days) hosts were removed from the lateral 
thoracic wall of recipient mice and grafted onto the 
flank of C57BL/6J-Rag KO mice. 
Preparation of purified T cell subsets and magnetic 
cell separation: CD8 T cells were purified as 
previously described [10]. After RBCs were lysed 
by hypotonic shock, lymph node and spleen cells 
were depleted of macrophages, granulocytes, B 
cells  and erythrocytes cells by incubating them first 
with anti-CD11b (Mac-1) Ab, anti-GR1 (8C5) Ab, 
anti-CD4 (GK1.5) Ab, anti-CD45R/B220 and anti-
erythrocytes Abs, and then with magnetic beads 
coupled to anti-rat Ig (Dynal). B cells were removed 
using magnetic beads coupled to anti-mouse IgG 
(Dynal).Purified CD8 T cells were negatively 
selected using MACS column (Miltenyi). The 
purity of the resultant CD8 T cells populations was 
determined by flow cytometry. A suspension of 
CD8 + T cells were resuspended in PBS/0.5% BSA 
(2 x 10
6
/ml) and stained with FITC-conjugated anti-
mouse CD8, on ice for 30 min, washed in 
PBS/BSA, and fixed in 1% formaldehyde before 
analysis. Purity was 95% in all experiments.  
Cell staining and flow cytometry: Pooled lymph 
nodes and spleen were homogenized in PBS 0.5% 
FCS 0.2% NaN3 with a nylon cell strainer (Falcon), 
and distributed in 96-well U-bottom microplates (4 
X10
6
 cells per well). Staining was performed on ice 
for 30 min per step. Abs were obtained from BD 
Pharmingen unless otherwise indicated. To prevent 
unspecific binding of mAb, all samples were 
preincubated with blocking anti-Fc-RII/III mAb 
(2.4G2). The following Abs combinations were 
used: for surface phenotype analysis, anti-CD8- 
CyChrome, anti-CD4- FITC, anti-CD3-PE, anti-
TCR-PE. All samples were analyzed using a 
FACSort equipped with CellQuest software (BD 
Biosciences, Mountain View, CA). Data were 
collected and analyzed by electronically gating on 
CD8 + populations. At least 100,000 events were 
collected for each sample. 
In vitro suppression assay: Spleen cells from 
DBA/2 (H-2
d
) or from C3H/He (H-2
k
) mice were 
depleted of T cells by anti- CD4/CD8 beads 
(Miltenyi), treated with Mitomycin C (Sigma) at 
50µg/mL for 30 min, and used as stimulators (4× 
10
5
) in round-bottomed 96-well plates. CD8 T cells 
were harvested as previously described [10] from 
CD4 KO mice either after long term engraftment of 
allogeneic skin transplant with RPM treatment or 
from naïve mice used as responders in a varying 
ratio (0, 1X10
5 
and
 
2X10
5 
) in MLR culture for 3 
days. Cells were pulsed with [3H] methylthymidine 
(0.5 µCi/well; NEN) for the last 12 h before 
 harvesting, and incorporated radioactivity of 
triplicate wells was counted. Data shown are 
representative of three separate experiments. 
Histopathology: The skin graft was removed from 
recipient LTE RPM treated CD4/KO mice 100 days 
post- transplantation, snap frozen and stored at -80 
Cº. Serial tissue sections (5 µ) were prepared and 
mounted on Super Frost Plus glass slides (Fisher 
Scientific, Pittsburgh, PA), fixed in formalin for 5 
min, and stained in H&E for histological evaluation. 
Immunohistochemistry:   The snap frozen tissue 
was cut into 5 micron sections, fixed in 2% 
paraformaldehyde,  rinsed in PBS, interacted with 
0.5% Triton X-100 treatment for 3 min.,  blocked 
30 minutes in 2% BSA and interacted with 1µg/ml 
anti- CD4 (BD Pharmingen cat# 550278) and anti-
CD8  (BD Pharmingen cat# 550281) monoclonal 
antibodies overnight at 4 Cº.  
 
Results 
 
1- RPM short term treatment can induce long term 
engraftment: 
It was reported that short term RPM can induce 
long term engraftment of a full mismatch allogeneic 
skin graft [9]. To examine if this LTE of skin graft 
have a functional (i.e. protecting vs rejecting) 
lymphocytic infiltrations, we transplanted two 
groups of B6 CD4 KO mice, 1
st
 group was 12 mice 
and the 2
nd
 group was 6 mice, with MHC 
mismatched DBA/2 skin. The 1st group was treated 
with RPM as described [9], while the 2
nd
 group was 
not treated. After 100 days of engraftment and long 
following cessation of RPM treatment, we 
challenged RPM treated hosts with a second DBA/2 
skin graft (n=6). Graft survival plotted. Both the 
initial and second DBA/2 grafts were rejected, but 
the newly implanted 2
nd
 grafts were rejected faster 
than the original graft P=0.05 (figure 1a & b). 
Perhaps the 1
st
 graft conducted in the context of 
RPM therapy harbored a CD8 T cells that are 
protective suppressor rather than rejecting.  
 
2- Functionally active immunoregulatory CD8 T 
cells reside in donor skin allograft and help long 
term engraftment in RPM CD4KO treated model: 
We next investigated whether the CD8 T cells home 
to LTE DBA/2 skin allografts and if they are 
functionally active protecting or rejecting the 
allografts. To test this hypothesis we transplanted a 
group with MHC mismatched DBA/2 skin (n = 15 
mice). This group was treated with RPM as 
previously described [9]. After 100 days of 
engraftment, we 1st harvested 3 different grafts for 
histopathology as previously described. The 
histopathology revealed that only grafts from LTE 
RPM treated hosts harbor CD8 +T cells, but not the 
control (Naïve DBA/2 tail skin) (figure 2 a & b).  
Then we investigated if the graft infiltrating CD8+ 
T cells are active in protecting rather than rejecting 
the LTE allograft. DBA/2 skin grafts were 
harvested 100 days post transplantation from (i) 
RPM treated B6 CD4 KO mice (n=5) and (ii) 
autologous DBA/2 ( this is DBA/2 skin graft onto 
DBA/2 mice) recipients (30 days post-
transplantation) (n= 5). As graft infiltrating CD8+ T 
cells emerge from the graft into the circulation of 
lympopenic hosts, LTE DBA/2 allografts or control 
DBA/2 autografts were then transplanted onto 
C57BL/6 RAG -/- hosts. A 3
rd
 control group of 
naïve DBA/2 skin grafts were transplanted onto 
C57BL/6-Rag-/- hosts (n=6). Next peripheral blood 
lymphocytes (PBL) samples were collected 30 days 
post skin transplantation. CD8+T cells could not be 
detected in PBL of naïve RAG-deficient mice, but 
4. 6 % CD8+ T cells are detected in PBL of 
C57BL/6-Rag -/- recipients of LTE allografts but 
not syngeneic grafts 30 days later  p <0.01 (figure 
3c & d). To test for protective function of graft 
homing CD8+ T cells (from LTE RPM treated 
mice) that expanded by homeostatic proliferation 
and are present in PBL of the C57 BL/6 Rag-/-, 0.2 
x 10
6
 CD8+ T cells from naive B6 CD4-deficient 
mice were adoptively transferred into the C57BL/6 
Rag -/- hosts bearing the LTE DBA/2 allografts or 
DBA/2 synegeneic grafts (30 days after syngeneic 
transplantation). Survival of LTE DBA/2 skin 
allografts transplanted onto C57BL/6 Rag -/- mice 
were significantly prolonged as compared to 
controls p=0.02 (figure 3e). This indicates that RPM 
treated full mismatch skin graft in CD4-deficient 
recipients are protected from rejection by graft 
infiltrating and functionally active CD8 regulatory 
T cells. 
 
3- CD8 T cells from long term engrafted RPM 
treated mice exert alloantigen specific 
hyporesponsivness:  
To investigate if the CD8 T cells from LTE RPM 
treated CD4 KO recipients of allograft have donor 
specific hyporesponsivness. We did in vitro MLR as 
previously described. Using splenocytes from either 
donor specific DBA/2 (H-2
d
) or from 3
rd
 party 
C3H/He (H-2
k
) mice as stimulators (4X10
5)
. The 
responders were CD8 T cells from CD4 KO mice 
(harvested as previously described) either after long 
term engraftment of allogeneic skin transplant with 
RPM treatment or from naïve mice used in a 
varying ratios (0, 1X10
5 
and
 
2X10
5 
) in MLR culture 
for 3 days. CD8 T cells from LTE mice were hypo-
 proliferative in response to DBA/2 donor strain but 
not to third party C3H stimulator cells as compared 
to the control CD8+ T cells from the naïve CD4 KO 
mice (figure 3).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1a. Challenging the RPM treated hosts harboring the 1st DBA/2 skin graft with a 2nd DBA/2 skin graft. The 2nd grafts were rejected 
faster than the original graft. Graft survival (days) was determined and presented as a Kaplan-Meier plot. P value between non Challenged 1st 
skin graft ( ) and challenged skin graft ( ) =0.004. P value between non Challenged 1st skin graft ( ) and same strain second graft 
( ) =0.006. P value between Challenged 1st skin graft ( ) and same strain second graft ( ) =0.05. 
 
 
Figure 2. Functionally active immunoregulatory 
CD8 cells reside in donor skin allograft and help 
long term engraftment in RPM CD4KO treated 
model  
 
 
Fig. 2a & b. Immuno-Histochemistry for CD8+ T cells are homing in (1ba) RPM long term engrafted and not in (1bb) normal skin graft. 
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Fig. 2c. P =< 0.01 between syngeneic & tolerant graft                                                         
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2d.  The graft survival is significantly longer in the C57 BL/6 Rag-deficient recipient bearing the LTE RPM treated graft compared to 
the control  p = 0.024 
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Fig. 3. CD8 T cells from LTE RPM treated mice are less proliferating (hyporesonsive) than naïve cell in antigen specific manner P (two way 
ANOVA) = 0.045 
 
 
Legends 
Figure 1a&b:- RPM short term treatment can induce long term engraftment: 
Two groups of C57 BL 6/CD4-deficient mice, 1st group was 12 mice and the 2nd  group was 6 mice, were transplanted with MHC mismatched DBA/2 skin. The 
1st group was treated with Rapamycin (RPM; 3mg/kg) for 3 consecutive days then every other day for two weeks, while the 2nd group was not treated. After 100 
days of engraftment, we challenged the RPM treated hosts with a 2nd DBA/2 skin graft (n=6). Graft survival (days) was determined and presented as a Kaplan-
Meier plot. The 2nd grafts were rejected faster than the original graft. CD8+ T cells reside in donor skin allograft and perhaps help long term engraftment in RPM 
CD4KO treated model. 
 
Figure 2:- Graft infiltrating CD8+ T cells home to the graft and are functionally active in protecting against rejection:  
A group of CD4 KO were transplanted with MHC mismatched DBA/2 skin (n=15). This group was treated with RPM. After 100 days of engraftment, we 1st 
harvested 3 different grafts for histopathology as previously described.  Immunohistochemistery was done for 3 different skin grafts harvested from LTE RPM 
treated mice and from naïve DBA/2 tails.  CD 8+ T cells have proven to be homed in the graft from LTE RPM treated mice, but not the control (Figure 2a & b). 
As graft infiltrating CD8+ T cells emerge from the graft into the circulation of lymphopenic hosts, LTE DBA/2 allografts (100 days posttransplantation N=5) or 
control DBA/2 autografts (30 days posttransplantation N=5) were harvested, then transplanted onto C57BL/6-Rag-/- hosts. A 3rd control group of naïve DBA/2 
skin grafts were transplanted onto C57BL/6-Rag-/- hosts (n=6). Next peripheral blood lymphocytes (PBL) samples were collected 30 days post skin 
transplantation. CD8+T cells could not be detected in PBL of naïve Rag-/- mice, but 4.6 % CD8+ TCR + T cells are detected in PBL of C57BL/6-Rag-/-
recipients of LTE allografts but not syngeneic grafts 30 days later (Figure 2c & d).  
To test for protective function in graft homing CD8+ T cells (from LTE RPM treated mice) that expanded by homeostatic proliferation and are present in PBL of 
the C57 BL/6 Rag -/-, 0.2 x 106 CD8+ T cells from naive B6 CD4KO mice were adoptively transferred into the C57BL/6-Rag -/- hosts bearing the long term 
engrafted DBA/2 allografts or DBA/2 syngeneic grafts (30 days after transplantation). Survival of LTE DBA/2 skin allografts transplanted onto C57BL/6-Rag -/- 
mice were significantly prolonged as compared to controls (figure 2c). RPM treated full mismatch skin graft in CD4 KO recipients are protected from rejection 
by graft infiltrating functionally active CD8 regulatory T cells.  
 
Figure 3:- CD8 T cells from long term engrafted RPM treated CD4KO mice exert a donor specific hyporesponsivness p = 0.04. 
In vitro MLR:  Varying ratios of CD8 T cells either naive or from CD4 KO mice harboring LTE RPM treated DBA/2 allogeneic skin graft were stimulated with 
Mitomycin C-treated DBA/2 (H-2d) or C3H/He (H-2k) splenocytes for 3 days. T-cell proliferation in these cultures as measured by the mean values of 
incorporated thymidine of triplicate wells, is compared in both groups. 
CD8+ T cells from RPM treated LTE mice are less proliferating (hyporesponsive) compared to the CD8+ T cells from the naïve CD4 KO mice when stimulated 
with DBA/2 splenocytes but not with C3H ones. Data represent three independent experiments. 
 
 
Discussion 
 
Subclinical rejection defined as asymptomatic 
tubulo-interstitial infiltrate usually occurs within 
the first three months after transplantation, and 
might be followed by worsening of 
tubulointerstitial damage, late graft dysfunction and 
inferior graft survival [3]. The only controlled trial 
of treatment of SCAR, a decade ago, showed that 
pulse administration of corticosteroids significantly 
have a non significant trend to better 4-year graft 
survival (P=0.076). However the control group in 
this study was not biopsied which douptly question 
the solidity of this conclusion [4]. 
The prevalence rates of SCAR in participants (who 
were receiving ciclosporin – azathioprine –
prednisone triple therapy) approximated 30%. This 
small, single-center study implied that protocol 
biopsies have a role in the detection and treatment 
of subclinical rejection [4]. A decade has passed 
since this study, and a second, multicenter trial 
from an expanded study group has now been 
published, showing a markedly different result: 
very low levels of SCAR (5.7–8.9%) and no 
MLR allogeneic (DBA/2 & C3H splenocytes)
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 apparent benefit of protocol biopsy [5]. 
Currently, inconclusive results have been shown by 
several studies evaluating the predictive value of 
SCAR on graft outcome [1,11-14]. Furthermore, 
this controversy is even more evident when the 
renal effect of treating or not treating SCAR is 
analyzed [15,16,1,17].This fact would support the 
results of previous experiences [15-16] in which 
after not treating the so-called SCAR, neither 
increase of interstitial fibrosis nor progressive loss 
of graft function was observed.  
In our study, we tried to study the functional effect 
of this skin allograft lymphocytic infiltration. 
Challenging the mice harboring a LTE RPM treated 
graft with same donor strain skin graft results in 
prolonged skin transplant compared to non treated 
same combination skin graft (Figure1a&b). 
Meanwhile, we noticed that the first skin graft can 
keep surviving longer than the challenging skin 
graft. One of the explanations is the effect of CD8 
T cells that are residing in the first skin graft and 
they are functionally active suppressor and exert a 
protecting effect that could allow the LTE of the 
graft. Garca et al., 2002 and our laboratory already 
reported that the CD4 residing in the graft 
considered as regulatory as they were exerting anti-
rejection protective effect that could help long term 
engraftment [18,19]. To test this hypothesis 
regarding the CD8 T cells, first immuno-
histochemistry of LTE graft showed abundance of 
the CD8+ T cells compared to the control naïve 
skin graft (figure 3 a & b). 
When we transplanted skin allografts from stable 
RPM LTE onto syngeneic immune-incompetent 
mice, graft-infiltrating T cells migrated from the 
graft site, expanded in the new host, and protected 
test allografts from acute rejection after transfer of 
naive syngeneic CD8 T cells (figure 3c, d & e). A 
similar finding concerning the CD4 regulatory T 
cells has been reported recently by Both Graca et al. 
[18] in a model of peripheral tolerance to minor 
histocompatibility Ag-mismatched skin allografts 
and by our laboratory [19] in a model in which skin 
allograft tolerance is achieved via BMT, RPM, and 
costimulation blockade. CD4 regulatory T cells are 
present in both secondary lymphoid organs and in 
the allograft itself, and are functionally active in 
protecting the grafts from rejection.  
Our finding may strengthen the outcome of a recent 
study published by  Bestard  et al in 2008 [20] who 
found that the  presence of Treg within 
asymptomatic cellular infiltrates in 6-mo protocol 
biopsies in kidney transplant patients may be a 
reliable biomarker for distinguishing an ongoing 
rejection/inflammatory process from a safe/ 
protective condition. This conclusion is supported 
by the better graft function evolution achieved at 
both 2 and 3 yr after transplantation in patients with 
Treg.  
A potential mechanistic explanation that could 
clarify this process is that donor-antigen recognition 
by Treg directly in the graft would be necessary for 
developing a donor-specific hyporesponsive state, 
mediated by the suppressive activity of these 
CD8Treg as we have shown in (figure 3). In the in 
vitro MLR, the CD8 T cells from LTE RPM treated 
mice are hyporesopnsive in an antigen specific 
manner compared to the control. This finding go in 
concordance with what was reported in recent 
studies, which showed that presence of Treg within 
tubulointerstitial infiltrates in a group of stable 
renal transplant patients in 6-mo protocol biopsies 
was associated with peripheral donor-specific 
hyporesponsiveness, which was mediated by the 
antidonor suppressive activity of Treg [21-22]. 
So, we conclude that T lymphocyte home to the 
skin graft and actively exert a protective effect 
against rejection. This conclusion open the door to 
readdress the issue of the hazardous effect of graft 
lymphocytic infiltration defined as subclinical 
rejection in kidney transplant patients. 
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